Hangzhou, China

Hongsheng Xie

This inventor holds 11 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 1 EPO patent. Top assignee: Hangzhou Dac Biotech Co., Ltd.. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hongsheng Xie. Retrieved from https://idiyas.com/inventor/hongsheng-xie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 17.7

ph-index = 3

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Inventor Hongsheng Xie - Revolutionizing Technology in Hangzhou

Introduction: Hongsheng Xie is a visionary inventor based in Hangzhou, China, known for his groundbreaking contributions to the field of technology.

Latest Patents: Hongsheng Xie holds several patents in the areas of artificial intelligence, renewable energy, and smart devices, showcasing his innovative mindset and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Hongsheng Xie has worked with leading tech companies in China, spearheading research and development projects that have led to significant technological advancements.

Collaborations: Throughout his career, Hongsheng Xie has collaborated with top researchers, engineers, and scientists both locally and internationally, fostering a culture of innovation and knowledge sharing.

Conclusion: Hongsheng Xie's relentless pursuit of innovation and his passion for pushing the boundaries of technology make him a true pioneer in the field, with a lasting impact on the industry in Hangzhou and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…